What Companies Are Legally Required to Disclose About GLP-1 Clinical Trials
U.S. law requires registration and results reporting for many clinical trials on ClinicalTrials.gov. Here's what that requirement actually covers.
By the GLP Semaglutide editorial team · Last updated September 10, 2025
Federal law (the FDA Amendments Act) requires sponsors of many clinical trials involving FDA-regulated products to register trials and report summary results on ClinicalTrials.gov, within specific timeframes tied to trial completion.
What's covered, and what isn't
The requirement generally applies to controlled trials of FDA-regulated drugs and devices studied in the U.S. or intended to support a U.S. marketing application; some early-phase or exploratory studies fall outside the mandatory registration requirement.
Why this matters for tracking GLP-1 pipeline news
ClinicalTrials.gov listings are a primary, legally mandated source for verifying a company's claims about an ongoing trial's design, phase, and status — a more reliable check than a press release alone.
Primary sources